Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Patients with advanced or metastatic urothelial cancer who had had a response to platinum-based chemotherapy were randomly assigned to best supportive care alone or best supportive care plus avelumab (an anti–PD-L1 antibody) every 2 weeks until progression. Patients receiving avelumab had significan...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 2020-09, Vol.383 (13), p.1218-1230 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Patients with advanced or metastatic urothelial cancer who had had a response to platinum-based chemotherapy were randomly assigned to best supportive care alone or best supportive care plus avelumab (an anti–PD-L1 antibody) every 2 weeks until progression. Patients receiving avelumab had significantly longer overall survival (21 months) than those receiving only best supportive care (14 months). |
---|---|
ISSN: | 0028-4793 1533-4406 1533-4406 |
DOI: | 10.1056/NEJMoa2002788 |